Companies: 10,795·Total market cap: $144.5T
HUTCHMED (China) Limited

HUTCHMED (China) Limited

HMDCFOTCHealthcare● Active
$2.90
+$0.74(+34.26%)
Market Cap$2.5B
P/E Ratio—
52W High$3.815
52W Low$2.16
ForecastMarket CapPE Ratio

HUTCHMED (China) Limited（HMDCF）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

hmdcf · 股价预测 · 3 位分析师（近3月）· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 3 位华尔街分析师

SellBuy

Buy

3 位分析师

共识

评级分布

Strong Buy
0
Buy
2
Hold
1
Sell
0
Strong Sell
0
合计: 3 · 买入占比: 66.7%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $2.16

HUTCHMED (China) Limited（HMDCF）的分析师共识为 Buy，基于过去 3 个月内 3 位华尔街分析师的评级。HMDCF 的 12 个月平均目标价为 $0.00，相对当前价 $2.16 代表 +0.0% 的潜在上行空间。

短期股价预测

Bear

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$2.05↓ 5.00%

1-day model range: $2.03–$2.07. Peak: $2.07 (-5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$2+3.2%
2028$2+5.1%
2029$2+6.3%
2030$2+7.1%
2031—+7.5%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

7%14%79%
1Buy
2Neutral
11Sell
RSI (14)0.0Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · HMDCF · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$2.16NEUTRAL
MA 10$2.16NEUTRAL
MA 20$2.42SELL
MA 50$2.66SELL
MA 100$2.82SELL
MA 200$3.17SELL
Current $HMDCF · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.17SELL
EMA 10$2.22SELL
EMA 20$2.36SELL
EMA 50$2.59SELL
EMA 100$2.80SELL
EMA 200$3.01SELL
Current $HMDCF · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Cantor Fitzgerald2023-09-04
Maintains
Overweight→Overweight
Cantor Fitzgerald2023-07-23
Maintains
Overweight→Overweight
Goldman Sachs2022-08-08
Maintains
Neutral→Neutral
Goldman Sachs2022-08-01
Maintains
Neutral→Neutral
Goldman Sachs2021-09-21
Downgrade ↓
Buy→Neutral
Canaccord Genuity2017-10-16
Maintains
Buy→Buy

Wall Street analysts have recently issued updated ratings on HUTCHMED (China) Limited (HMDCF) stock. Of the recent 6 rating actions, 0 were upgrades and 1 were downgrades. 3 analysts currently cover HMDCF.

分析师推荐趋势

Buy ratings1 → 1
Hold ratings0 → 0
Sell ratings0 → 0

HMDCF analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$638M

↓ 23.4% YoY

Revenue Next Year

$737M

↑ 15.4% YoY

EPS This Year

$0.06

EPS Next Year

$0.09

↑ 43.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast HMDCF EPS of $0.06 for the current fiscal year, based on estimates from 1 analysts. The HMDCF revenue forecast is $638M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

HMDCF 股价预测由两类独立数据源支撑：来自 3 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。HMDCF 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。

HMDCF 的短期预测（明日）为 $2.05（-5.00%）。 HMDCF 对 2027 年的股价预测均值为 $2。 HMDCF 对 2030 年的预测区间为 $2–$3。

HUTCHMED (China) Limited 在 OTC 上市，代码 HMDCF。HMDCF 在 2027 年的整体展望偏积极，在覆盖分析师中约 67% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

HMDCF 预测 · 8 个问题

根据 3 位华尔街分析师，HMDCF 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $2.16，隐含约 +0.0% 的上行空间。

HMDCF 目标价HMDCF 分析师目标价HMDCF 12个月目标价目标价 HMDCF

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.